Publications

BibTex format

@article{Ferreira:2020:10.1002/ehf2.12521,
author = {Ferreira, JP and Duarte, K and Woehrle, H and Cowie, MR and Wegscheider, K and Angermann, C and d'Ortho, M-P and Erdmann, E and Levy, P and Simonds, AK and Somers, VK and Teschler, H and Rossignol, P and Koenig, W and Zannad, F},
doi = {10.1002/ehf2.12521},
journal = {ESC Heart Failure},
pages = {503--511},
title = {Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial},
url = {http://dx.doi.org/10.1002/ehf2.12521},
volume = {7},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AimsThe Treatment of SleepDisordered Breathing with Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients with Heart Failure trial investigated the effects of adaptive servoventilation (ASV) (vs. control) on outcomes of 1325 patients with heart failure and reduced ejection fraction (HFrEF) and central sleep apnoea (CSA). The primary outcome (a composite of allcause death or unplanned HF hospitalization) did not differ between the two groups. However, allcause and cardiovascular (CV) mortality were higher in the ASV group. Circulating biomarkers may help in better ascertain patients' risk, and this is the first study applying a large set of circulating biomarkers in patients with both HFrEF and CSA.Methods and resultsCirculating proteinbiomarkers (n = 276) ontologically involved in CV pathways, were studied in 749 (57% of the trial population) patients (biomarker substudy), to investigate their association with the study outcomes (primary outcome, CV death and allcause death). The mean age was 69 ± 10 years, and > 90% were male. The groups (ASV vs. control and biomarker substudy vs. no biomarker) were well balanced. The “best” clinical prognostic model included male sex, systolic blood pressure < 120 mmHg, diabetes, loop diuretic, cardiac device, 6min walking test distance, and Nterminal pro BNP as the strongest prognosticators. On top of the “best” clinical prognostic model, the biomarkers that significantly improved both the discrimination (cindex) and the net reclassification index (NRI) of the model were soluble suppression of tumorigenicity 2 for the primary outcome; neurogenic locus notch homolog protein 3 (Notch3) for CVdeath and allcause death; and growth differentiation factor 15 (GDF15) for allcause death only.ConclusionsWe studied 276 circulating biomarkers in patients with HFrEF and central sleep apnoea; of these biomarkers, three added significant prognostic information on top of the
AU  - Ferreira,JP
AU  - Duarte,K
AU  - Woehrle,H
AU  - Cowie,MR
AU  - Wegscheider,K
AU  - Angermann,C
AU  - d'Ortho,M-P
AU  - Erdmann,E
AU  - Levy,P
AU  - Simonds,AK
AU  - Somers,VK
AU  - Teschler,H
AU  - Rossignol,P
AU  - Koenig,W
AU  - Zannad,F
DO  - 10.1002/ehf2.12521
EP  - 511
PY  - 2020///
SN  - 2055-5822
SP  - 503
TI  - Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial
T2  - ESC Heart Failure
UR  - http://dx.doi.org/10.1002/ehf2.12521
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000507667000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.12521
UR  - http://hdl.handle.net/10044/1/78672
VL  - 7
ER  -

Download

Emeritus ProfessorAnitaSimonds

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)